Literature DB >> 9010119

Patients excluded from an antidepressant efficacy trial.

T Partonen1, S Sihvo, J K Lönnqvist.   

Abstract

BACKGROUND: The impact of exclusion criteria on antidepressant trials is rarely investigated and poorly understood. We describe specific reasons for exclusion from a double-blind comparative trial and analyze the selection procedure and its impact on treatment outcome.
METHOD: A 6-week randomized double-blind trial for depressive disorders recruited patients through outpatient psychiatric services, private offices, and health care centers. Of the 612 consecutive patients interviewed for a diagnosis according to DSM-III-R, 209 (34%) finally entered the trial.
RESULTS: 86% of the included patients had no comorbid psychiatric disorder, whereas a third of those excluded had at least one (p < .00001). Patients were excluded for having chronic alcohol or drug misuse (17%), receiving antidepressant drugs (15%), or having physical problems precluding their ability to take either of the drugs studied (14%). Some patients could not be included because of a referral to other modes of treatment (19%) or organizational difficulties (16%). The excluded patients less often suffered from major depressive disorder than those who were included in the trial. In particular, patients excluded because of suicidal thoughts or intent more often had a history of previous major depressive episodes (p = .006) compared with the included patients. The most important sociodemographic factors related to exclusion from the trial were male sex and unmarried status.
CONCLUSION: Patients with previous depressive episodes or comorbid disorders were more likely to be excluded from the antidepressant efficacy trial. Data on the efficacy of antidepressant drugs on this patient population are still only infrequently obtained.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9010119     DOI: 10.4088/jcp.v57n1203

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  7 in total

Review 1.  Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity.

Authors:  Mark Zimmerman; Matthew Multach; Emily Walsh; Lia K Rosenstein; Douglas Gazarian; Heather L Clark
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 5.749

2.  Treatment of late-life depression complicated by alcohol dependence.

Authors:  David W Oslin
Journal:  Am J Geriatr Psychiatry       Date:  2005-06       Impact factor: 4.105

3.  The Psychiatric Inclusion and Exclusion Criteria in Placebo-Controlled Monotherapy Trials of Bipolar Depression: An Analysis of Studies of the Past 20 Years.

Authors:  Mark Zimmerman; Carolina Guzman Holst; Heather L Clark; Matthew Multach; Emily Walsh; Lia K Rosenstein; Douglas Gazarian
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

4.  From Randomized Controlled Trials of Antidepressant Drugs to the Meta-Analytic Synthesis of Evidence: Methodological Aspects Lead to Discrepant Findings.

Authors:  Konstantinos N Fountoulakis; Roger S McIntyre; André F Carvalho
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

5.  The generalizability of psychotherapy efficacy trials in major depressive disorder: an analysis of the influence of patient selection in efficacy trials on symptom outcome in daily practice.

Authors:  Rosalind van der Lem; Wouter Wh de Wever; Nic Ja van der Wee; Tineke van Veen; Pim Cuijpers; Frans G Zitman
Journal:  BMC Psychiatry       Date:  2012-11-08       Impact factor: 3.630

Review 6.  Incomplete remission in depression: role of psychiatric and somatic comorbidity.

Authors:  Christian Otte
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

7.  Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS.

Authors:  N Bijker; J L Peterse; I S Fentiman; J-P Julien; A A M Hart; A Avril; L Cataliotti; E J T Rutgers
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.